<DOC>
	<DOC>NCT02137343</DOC>
	<brief_summary>This is a Phase 3, multicenter, randomized, double-blind, placebo controlled study of Rilotumumab (AMG 102) with Cisplatin and Capecitabine (CX) for untreated advanced mesenchymal epithelial transition factor (MET)-positive gastric or gastroesophageal junction adenocarcinoma (GEJ).</brief_summary>
	<brief_title>A Phase 3 Study of Rilotumumab (AMG 102) With Cisplatin and Capecitabine (CX) as First-line Therapy in Gastric Cancer</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Key Pathologically confirmed unresectable locally advanced or metastatic gastric or GEJ adenocarcinoma. Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1. Tumor METpositive by immunohistochemistry (IHC). Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. Male or female subject greater than or equal to 20 years of age at the time of informed consent. Key Human epidermal growth factor receptor 2 (HER2)overexpressing locally advanced or metastatic gastric or GEJ adenocarcinoma. Previous systemic therapy for locally advanced or metastatic gastric or GEJ or lower esophageal adenocarcinoma. Less than 6 months have elapsed from completion of prior neoadjuvant or adjuvant chemotherapy or chemoradiotherapy to randomization. Squamous cell histology.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Gastric Cancer</keyword>
	<keyword>First Line Treatment Gastroesophageal Junction (GEJ)</keyword>
	<keyword>Gastroesophageal Junction Cancer (GEJ)</keyword>
	<keyword>GEJ Cancer</keyword>
</DOC>